Anti-Human CD269/TNFRSF17/BCMA Antibody (SAA0086)

Catalog No.

FHF92410

Species reactivity

Human

Host species

Human

Isotype

IgG1, kappa

Clonality

Monoclonal

Conjugation

Unconjugated

Target

Tumor necrosis factor receptor superfamily member 17, TNFRSF17, CD269, B-cell maturation protein, BCMA, BCM

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

Q02223

Applications

FCM

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Clone ID

SAA0086

An Anti-BCMA Affibody Affinity Protein for Therapeutic and Diagnostic Use in Multiple Myeloma., PMID:40507995

BCMA-targeted therapies in multiple myeloma: advances, challenges and future prospects., PMID:40338452

BCMA-targeted therapies for multiple myeloma: latest updates from 2024 ASH annual meeting., PMID:40025529

Population Pharmacokinetics of Orvacabtagene Autoleucel, an Autologous BCMA-Directed Chimeric Antigen Receptor T-cell Product, in Patients with Relapsed/Refractory Multiple Myeloma., PMID:39836430

Mechanisms for resistance to BCMA-targeted immunotherapies in multiple myeloma., PMID:39818472

Update on B-cell maturation antigen-directed therapies in AL amyloidosis., PMID:39748220

Dual-targeted STAb-T cells secreting BCMA and CD19 T cell engagers for improved control of haematological cancers., PMID:39723764

Anti-BCMA and GPRC5D bispecific antibodies in relapsed/refractory primary plasma cell leukemia: a case report., PMID:39676854

Targeting human plasma cells using regulated BCMA CAR T cells eliminates circulating antibodies in humanized mice., PMID:39673129

Clinical updates of B‑cell maturation antigen‑targeted therapy in multiple myeloma (MM) and relapsed/refractory MM (Review)., PMID:39670288

Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy., PMID:39632797

BCMA-Directed MRD Detection as a Predictor of Relapse after BCMA CAR T in Multiple Myeloma., PMID:39516088

Enhanced cytotoxicity in multiple myeloma via T cells armed with bispecific T cell engager targeting B-cell maturation antigen on cancer cells and CD3 on T cells., PMID:39467352

Trispecific anti-CD3/BCMA/CD38 antibodies for multiple myeloma: a patent evaluation of US20240132615., PMID:39460602

B-Cell Maturation Antigen (BCMA) as a Biomarker and Potential Treatment Target in Systemic Lupus Erythematosus., PMID:39409173

Phase 1 first-in-human study of MEDI2228, a BCMA-targeted ADC, in patients with relapsed refractory multiple myeloma., PMID:39404476

Single-cell analysis of the multiple myeloma microenvironment after γ-secretase inhibition and CAR T-cell therapy., PMID:39374522

B-Cell Maturation Antigen-Directed Immunotherapies for the Treatment of Relapsed/Refractory Multiple Myeloma: A Review of the Literature and Implications for Clinical Practice., PMID:39373355

Preclinical Evaluation of STI-8811, a Novel Antibody-Drug Conjugate Targeting BCMA for the Treatment of Multiple Myeloma., PMID:39292169

Interferon Regulatory Factor 4: An Alternative Marker for Plasma Cells in Daratumumab-Treated Patients With Multiple Myeloma., PMID:39267340

Current status of BAFF targeting immunotherapy in B-cell neoplasm., PMID:39222149

Efficacy and safety of teclistamab in patients with relapsed/refractory multiple myeloma after BCMA-targeting therapies., PMID:39172760

Management of Toxicities Associated with BCMA, GPRC5D, and FcRH5-Targeting Bispecific Antibodies in Multiple Myeloma., PMID:39145912

Clinical features associated with poor response and early relapse following BCMA-directed therapies in multiple myeloma., PMID:39043638

Just scratching the surface: novel treatment approaches for multiple myeloma targeting cell membrane proteins., PMID:38961233

Informing the Recommended Phase III Dose of Alnuctamab, a CD3 × BCMA T-Cell Engager, Using Population Pharmacokinetics and Exposure-Response Analysis., PMID:38938115

Anti-BCMA-engineered exosomes for bortezomib-targeted delivery in multiple myeloma., PMID:38875465

Beyond BCMA: newer immune targets in myeloma., PMID:38865708

Comparison of infectious complications with BCMA-directed therapies in multiple myeloma., PMID:38821925

BCMA/CD47-directed universal CAR-T cells exhibit excellent antitumor activity in multiple myeloma., PMID:38783333

Current progress of CAR-T-cell therapy for patients with multiple myeloma., PMID:38777913

BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial., PMID:38777376

Antigen escape as a shared mechanism of resistance to BCMA-directed therapies in multiple myeloma., PMID:38728378

Therapeutic potential of third-generation chimeric antigen receptor T cells targeting B cell maturation antigen for treating multiple myeloma., PMID:38683232

Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in the MajesTEC-1 study., PMID:38657201

Effectiveness and infectious complications of BCMA T-cell engagers in treating multiple myeloma: Real-world evidence from Sweden., PMID:38651177

Real-World Data on Therapies for Relapsed or Refractory Multiple Myeloma: Key Data from ASH 2023-A Podcast., PMID:38642197

Soluble B-cell maturation antigen in lacrimal fluid as a potential biomarker and mediator of keratopathy in multiple myeloma., PMID:38572568

Impact of Treatment Modality and Route of Administration on Cytokine Release Syndrome in Relapsed or Refractory Multiple Myeloma: A Meta-Analysis., PMID:38459622

Serum levels and significance of soluble B-cell maturation antigen in childhood-onset systemic lupus erythematosus with renal involvement., PMID:36914971

B cell-specific mAb-siRNA conjugates improve experimental myasthenia., PMID:36640636

Expression levels and patterns of B-cell maturation antigen in newly diagnosed and relapsed multiple myeloma patients from Indian subcontinent., PMID:36346307

Teclistamab in Relapsed or Refractory Multiple Myeloma., PMID:35661166

Serum B-Cell maturation antigen is an independent prognostic marker in previously untreated chronic lymphocytic leukemia., PMID:35525334

Targeting BCMA in Multiple Myeloma., PMID:34432234

[The Significance of CD319 and CD269 in the Detection of Immunophenotyping and Minimal Residual Disease in Multiple Myeloma Patients]., PMID:34362502

Endogenous soluble receptors sBCMA and sTACI: biomarker, immunoregulator and hurdle for therapy in multiple myeloma., PMID:34330018

BCMA-Specific ADC MEDI2228 and Daratumumab Induce Synergistic Myeloma Cytotoxicity via IFN-Driven Immune Responses and Enhanced CD38 Expression., PMID:34301753

Belantamab Mafodotin (GSK2857916) Drives Immunogenic Cell Death and Immune-mediated Antitumor Responses In Vivo., PMID:34253590

Document Download

Anti-Human CD269/TNFRSF17/BCMA Antibody (SAA0086).pdf